Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Verona Pharma plc is a biotechnology business based in the US. Verona Pharma shares (VRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Verona Pharma employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $5.82 |
|---|---|
| 52-week range | $5.40 - $9.72 |
| 50-day moving average | $6.31 |
| 200-day moving average | $7.38 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.34 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.82 from 2021-05-26
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | -2.51% |
| 3 months (2021-05-05) | -7.77% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -37.8% |
| Return on equity TTM | -72.44% |
| Profit margin | 0% |
| Book value | $2.97 |
| Market capitalisation | $347.7 million |
TTM: trailing 12 months
There are currently 206,475 Verona Pharma shares held short by investors – that's known as Verona Pharma's "short interest". This figure is 12.6% down from 236,166 last month.
There are a few different ways that this level of interest in shorting Verona Pharma shares can be evaluated.
Verona Pharma's "short interest ratio" (SIR) is the quantity of Verona Pharma shares currently shorted divided by the average quantity of Verona Pharma shares traded daily (recently around 62758.358662614). Verona Pharma's SIR currently stands at 3.29. In other words for every 100,000 Verona Pharma shares traded daily on the market, roughly 3290 shares are currently held short.
However Verona Pharma's short interest can also be evaluated against the total number of Verona Pharma shares, or, against the total number of tradable Verona Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verona Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Verona Pharma shares in existence, roughly 0 shares are currently held short) or 0.0063% of the tradable shares (for every 100,000 tradable Verona Pharma shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verona Pharma.
Find out more about how you can short Verona Pharma stock.
We're not expecting Verona Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Verona Pharma's shares have ranged in value from as little as $5.4 up to $9.722. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verona Pharma's is 0.5145. This would suggest that Verona Pharma's shares are less volatile than average (for this exchange).
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
